EGFR and lung cancer: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as first generation gefitinib/erlotinib and second generation afatinib showed remarkable activity in EGFR-mutant lung cancer patients with or without CNS metastasis [4, 5, 6].